In today’s recent session, 0.67 million shares of the Intellia Therapeutics Inc (NASDAQ:NTLA) have been traded, and its beta is 2.14. Most recently the company’s share price was $9.24, and it changed around $0.24 or 2.66% from the last close, which brings the market valuation of the company to $956.45M. NTLA at last check was trading at a discount to its 52-week high of $28.23, offering almost -205.52% off that amount. The share price’s 52-week low was $8.30, which indicates that the recent value has risen by an impressive 10.17% since then. We note from Intellia Therapeutics Inc’s average daily trading volume that its 10-day average is 2.81 million shares, with the 3-month average coming to 3.15 million.
Intellia Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.69. If we narrow it down even further, the data shows that 0 out of 29 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 7 recommended NTLA as a Hold, whereas 17 deemed it a Buy, and 1 rated it as Underweight. Intellia Therapeutics Inc is expected to report earnings per share of -1.26 for the current quarter.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Instantly NTLA has been showing a green trend so far today with a performance of 2.66% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 9.47 on recent trading dayincreased the stock’s daily price by 2.43%. The company’s shares are currently down -20.76% year-to-date, but still down -3.55% over the last five days. On the other hand, Intellia Therapeutics Inc (NASDAQ:NTLA) is -24.08% down in the 30-day period. We can see from the shorts that 26.04 million shares have been sold at a short interest cover period of 7.91 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 58.0% from its current value. Analyst projections state that NTLA is forecast to be at a low of $9 and a high of $60.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
The year-over-year growth rate is expected to be -17.91%, down from the previous year.
Consensus estimates provided by 20 financial analysts predict the company will bring in an average of 11.39M in revenue for the current quarter. 20 analysts expect Intellia Therapeutics Inc to make 11.37M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 28.93M and 6.96M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -60.65%. Forecasts for the next quarter put sales growth at 63.41%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.04%. Intellia Therapeutics Inc earnings are expected to increase by 11.04% in 2025, but the outlook is positive 25.47% per year for the next five years.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.05% of Intellia Therapeutics Inc shares, and 91.72% of them are in the hands of institutional investors. The stock currently has a share float of 96.60%. Intellia Therapeutics Inc stock is held by 417.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 11.9575% of the shares, which is about 11.6 million shares worth $259.51 million.
BLACKROCK INC., with 10.0496% or 9.6 million shares worth $214.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK Innovation ETF and ARK Genomic Revolution ETF were the top two Mutual Funds as of Feb 28, 2025. The former held 8.72 shares worth $80.3 million, making up 8.42% of all outstanding shares. On the other hand, ARK Genomic Revolution ETF held roughly 3.09 shares worth around $28.42 million, which represents about 2.98% of the total shares outstanding.
